PLEASE GIVE TO RSDSA – donor will match donations up to $5,000!


.

.

.

Neuropathic Pain is

.

highly difficult to treat 

.

and few medications are available

.

.

Please donate to RSDSA to support research for neuropathic pain & help those disabled by pain.

 

 

From RSDSA:

 

It’s almost go time!

 

We are only days away from #GivingTuesday 2019! This year, we have a donor who will match our donations up to $5,000! It’s true that it takes a village like our community to work together and raise awareness, educate, and advocate for better treatments.

 

If you haven’t done so already, please make a donation to our #GivingTuesday fundraising page and tell your friends and family about our campaign. Spreading the word gets our voices heard and the donations rolling in! We’re excited to be a part of this worldwide event and providing a chance to give back to our community.

 

Please join our campaign between now

 and Tuesday, December 3, 2019

 

RSDSA’s 2019 Accomplishments

 

  • Co-sponsorship of Courageous Kids Camp for children with CRPS in Kentucky for the 4th year

  • Sponsorship of Young Adults Weekends for young adults with CRPS who are transitioning into the workforce, independent living, and other new situations

  • Sponsorship of an accredited free online course on pediatric CRPS

  • Sponsorship of two Treating the Whole Person conferences; in Houston and Denver

  • And much more!

    .
    .

Cheers,

.

.

Your Team at RSDSA

 

 

 

 

 .

.

 

.

 

.

 

We are highlighting a different Warrior’s story on our blog each day!

.

.

Catch up on the posts today!

.

.

.

.

.

.

.

.

.

.

The material on this site is for informational purposes only.

.

It is not legal for me to provide medical advice without an examination.

.

It is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.

~~

Comments are welcome.

This site is not for email, not for medical questions, and not for appointments.

~~~~~

For My Home Page, click here:  Welcome to my Weblog on Pain Management!

.

Please IGNORE THE ADS BELOW. They are not from me.

.

.

.

.

.

.

.

.

.

.

.

 

Tell the FDA There is an Urgent Need for New Options for Pain – DEADLINE TODAY


.

.

.

TODAY IS THE DEADLINE


Electronic comments can be submitted here. Again, the deadline is Monday at 11:59 PM EST.

.

Your comment doesn’t have to be long to make a difference.

Tell the FDA There is an Urgent Need for New Options for Pain

 

from

Cindy Steinberg, National Director of Policy & Advocacy,

US Pain Foundation

 

 

At the U.S. Pain Foundation, we often send out notifications to the pain community about opportunities to take action on pain-related issues at the federal level. Most people, if they are anything like me before I became an advocate, assume weighing in on these opportunities doesn’t make a difference.

 

I want you to know that it does! Your voice really does matter. Federal agencies have rules for how they must handle responses to public comment periods. They are required to review and consider public comments in their final rulemaking. Typically, comments are read and then categorized according to key topics or concerns within the comments. If 1,000 people write in about a key topic or concern, it gets attention. At the very least, a large response to a comment period lets the agency know that many people are paying attention to what they are doing and will want to see their views reflected in the final product.

 

With that in mind, I want to encourage all people with pain to submit their comments about the urgent need for new medication options for pain relief to the Food and Drug Administration (FDA) by this Monday, Nov. 18, at 11:59 pm EST. Specifically, the FDA would like the public’s views on two main issues:

 

  1. Should sponsors of new opioids be required to demonstrate comparative advantage relative to existing opioids?

  2. What incentives would better support and encourage the development of new treatments for pain?

This comment opportunity comes on the heels of a Sept. 17 public hearing at the FDA, called “Standards for Future Opioid Analgesic Approvals and Incentives for New Therapeutics to Treat Pain and Addiction.” At this hearing, many different views on these questions from various individuals and organizations were presented. For example, some people said that no new opioids should be approved and that existing opioids should be reconsidered for possible removal. Others said that there has been a drought of innovation in pain therapeutics and that FDA should do more to encourage innovation.

 

Sadly, it is true that there has long been a dearth of new safe, effective medications approved for pain. We encourage you to tell FDA what impact pain has had on your life and how speeding up the development of new drugs in the pipeline could make a difference to your life and the lives of so many others debilitated by chronic pain.

 

Electronic comments can be submitted here. Again, the deadline is Monday at 11:59 PM EST.

 

Your comment doesn’t have to be long to make a difference. What’s most important is that you submit one. This is one way that you can contribute to a better future for people with pain.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.


The material on this site is for informational purposes only.

.
It is not legal for me to provide medical advice without an examination.

.
It is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.

~~~~~

For My Home Page, click here:  

Welcome to my Weblog on Pain Management!

 

Please ignore the ads below. They are not from me.

..

.

.

 

 

 

THE ADVERTISING BELOW IS NOT FROM ME.

CBD efficacy on nonmotor symptoms of Parkinson Disease anxiety & psychosis


.

.

.

This is the last section of a review article Managing Psychosis in Parkinson Disease

.

Results from preclinical and preliminary studies also suggest that cannabidiol (CBD) has therapeutic potential for nonmotor symptoms of PD.14 The multifaceted mechanism of action as an agonist of 5-HT1A, partial agonist of CB1 and CB2 receptors, and antagonist of the G-protein–coupled receptor GPR55 reverses the iron-induced epigenetic modification of mitochondrial DNA and the reduction of succinate dehydrogenase activity and decreases the levels of the pro-inflammatory cytokines IL-1β, TNF-α, IFN-β, IFN-γ, IL-17, and IL-6—all of which decrease pro-inflammatory mediators resulting in neuroprotective, anxiolytic, and antipsychotic effects.14

.

“Several in vitro experiments have demonstrated promising neuro- protective effects of CBD in PD models. In one of these models, using PC12 and SH-SY5Y cells treated with MPP+ [1-methyl-4-phenylpyridinium], CBD increased cell viability, differentiation, and the expression of axonal [GAP-43] and synaptic [synaptophysin and synapsin I] proteins,” Ferreria-Junior and colleagues wrote,15 while acknowledging the paucity of studies that have addressed the biological bases for the purported effects of CBD on PD. “Double-blind, placebo-controlled, randomized trials with larger samples of patients with PD are needed to elucidate the possible effectiveness and mechanisms involved in the therapeutic potential of CBD in this movement disorder. This will also include the putative effects of CBD in preventing L-dopa–induced severe [adverse] effects and preventing PD progression.”

.

The endocannabinoid system serves as an important filter of excitatory, inhibitory, and modulatory inputs that act at the midbrain and terminal regions to orchestrate DA neurotransmission by controlling DA cell body firing patterns, terminal release, and effects on postsynaptic sites in the striatum.16 Beneficial effects of CBD administration have been observed prior to or immediately after induction of PD-like symptoms in animal studies, which may suggest a preventive role rather than a therapeutic one.14 In an early open-label pilot study to evaluate the efficacy of CBD on nonmotor symptoms of PD in 6 patients with PDP, psychotic symptoms significantly decreased under CBD treatment, as evaluated by the brief psychiatric rating scale and the Parkinson psychosis questionnaire.17

 

………..

 

Psychiatric comorbidities prevalent in the majority of patients with PD are associated with more disease severity, impaired QOL, and increased use of healthcare resources, with longer hospital stays and re-hospitalizations adding to the total cost burden.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

 


The material on this site is for informational purposes only.

.
It is not legal for me to provide medical advice without an examination.

.
It is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.

~~~~~

For My Home Page, click here:  

Welcome to my Weblog on Pain Management!

..

.

.

.

.

..

.

.

.

.

.

.

 

 

%d bloggers like this: